Results 201 to 210 of about 276,777 (390)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

open access: yesJACC. CardioOncology, 2019
Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung cancer. Background:
Kalyan R. Chitturi, DO   +8 more
doaj  

Troponin-Tropomyosin Complex

open access: hybrid, 1974
Evan Eisenberg, W. Wayne Kielley
openalex   +1 more source

Cardiac damage biomarkers and heart rate variability following a 118-km mountain race: relationship with performance and recovery [PDF]

open access: yes, 2019
This study aimed to assess the release of cardiac damage biomarkers jointly with cardiac autonomic modulation after a mountain ultramarathon. Such knowledge and the possible relationship of these markers with race time is of primary interest to establish
Collado-Boira, Eladio   +4 more
core   +1 more source

Takotsubo cardiomyopathy during armed conflict: A case series

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha   +13 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy